Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405

Marla Lipsyc-Sharf; Sui Zhang; Fang Shu Ou; Chao Ma; Nadine Jackson McCleary; Donna Niedzwiecki; I. Wen Chang; Heinz Josef Lenz; Charles D. Blanke; Sorbarikor Piawah; Katherine Van Loon; Tiffany M. Bainter; Alan P. Venook; Robert J. Mayer; Charles S. Fuchs; Federico Innocenti; Andrew B. Nixon; Richard Goldberg; Eileen M. O'Reilly; Jeffrey A. Meyerhardt; Kimmie Ng

doi:10.1093/jnci/djab200

Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405

Marla Lipsyc-Sharf, Sui Zhang, Fang Shu Ou, Chao Ma, Nadine Jackson McCleary, Donna Niedzwiecki, I. Wen Chang, Heinz Josef Lenz, Charles D. Blanke, Sorbarikor Piawah, Katherine Van Loon, Tiffany M. Bainter, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Federico Innocenti, Andrew B. Nixon, Richard Goldberg, Eileen M. O'Reilly, Jeffrey A. MeyerhardtKimmie Ng

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Background: The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC). Methods: We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided. Results: Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P =. 78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P =. 67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend =. 93). Conclusion: In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.

Original language	English (US)
Pages (from-to)	427-435
Number of pages	9
Journal	Journal of the National Cancer Institute
Volume	114
Issue number	3
DOIs	https://doi.org/10.1093/jnci/djab200
State	Published - Mar 1 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/jnci/djab200

Cite this

Lipsyc-Sharf, M., Zhang, S., Ou, F. S., Ma, C., McCleary, N. J., Niedzwiecki, D., Chang, I. W., Lenz, H. J., Blanke, C. D., Piawah, S., Van Loon, K., Bainter, T. M., Venook, A. P., Mayer, R. J., Fuchs, C. S., Innocenti, F., Nixon, A. B., Goldberg, R., O'Reilly, E. M., ... Ng, K. (2022). Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 114(3), 427-435. https://doi.org/10.1093/jnci/djab200

Lipsyc-Sharf, M, Zhang, S, Ou, FS, Ma, C, McCleary, NJ, Niedzwiecki, D, Chang, IW, Lenz, HJ, Blanke, CD, Piawah, S, Van Loon, K, Bainter, TM, Venook, AP, Mayer, RJ, Fuchs, CS, Innocenti, F, Nixon, AB, Goldberg, R, O'Reilly, EM, Meyerhardt, JA & Ng, K 2022, 'Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405', Journal of the National Cancer Institute, vol. 114, no. 3, pp. 427-435. https://doi.org/10.1093/jnci/djab200

@article{4c88fc9638bb45149ce1a5234cbd7c6f,

title = "Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405",

abstract = "Background: The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC). Methods: We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided. Results: Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P =. 78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P =. 67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend =. 93). Conclusion: In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.",

author = "Marla Lipsyc-Sharf and Sui Zhang and Ou, {Fang Shu} and Chao Ma and McCleary, {Nadine Jackson} and Donna Niedzwiecki and Chang, {I. Wen} and Lenz, {Heinz Josef} and Blanke, {Charles D.} and Sorbarikor Piawah and {Van Loon}, Katherine and Bainter, {Tiffany M.} and Venook, {Alan P.} and Mayer, {Robert J.} and Fuchs, {Charles S.} and Federico Innocenti and Nixon, {Andrew B.} and Richard Goldberg and O'Reilly, {Eileen M.} and Meyerhardt, {Jeffrey A.} and Kimmie Ng",

year = "2022",

month = mar,

day = "1",

doi = "10.1093/jnci/djab200",

language = "English (US)",

volume = "114",

pages = "427--435",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Survival in Young-Onset Metastatic Colorectal Cancer

T2 - Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405

AU - Lipsyc-Sharf, Marla

AU - Zhang, Sui

AU - Ou, Fang Shu

AU - Ma, Chao

AU - McCleary, Nadine Jackson

AU - Niedzwiecki, Donna

AU - Chang, I. Wen

AU - Lenz, Heinz Josef

AU - Blanke, Charles D.

AU - Piawah, Sorbarikor

AU - Van Loon, Katherine

AU - Bainter, Tiffany M.

AU - Venook, Alan P.

AU - Mayer, Robert J.

AU - Fuchs, Charles S.

AU - Innocenti, Federico

AU - Nixon, Andrew B.

AU - Goldberg, Richard

AU - O'Reilly, Eileen M.

AU - Meyerhardt, Jeffrey A.

AU - Ng, Kimmie

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Background: The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC). Methods: We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided. Results: Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P =. 78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P =. 67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend =. 93). Conclusion: In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.

AB - Background: The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC). Methods: We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided. Results: Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P =. 78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P =. 67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend =. 93). Conclusion: In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.

UR - http://www.scopus.com/inward/record.url?scp=85125965880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125965880&partnerID=8YFLogxK

U2 - 10.1093/jnci/djab200

DO - 10.1093/jnci/djab200

M3 - Article

C2 - 34636852

AN - SCOPUS:85125965880

SN - 0027-8874

VL - 114

SP - 427

EP - 435

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 3

ER -

Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this